This premium U.S.-based manufacturer specializes in advanced prosthetic foot technology, offering lower-limb solutions for amputees. With 25 CMS-approved PDAC billing codes and the highest margin structure in the prosthetic foot segment, the company is strategically positioned within the rapidly expanding $1.6 billion diabetic foot loss market.

The business delivers high reimbursement potential, strong price-to-value economics, and some of the most natural-feeling prosthetic foot systems available. Products are engineered using aerospace-derived composite materials, ensuring lightweight strength, superior flexibility, and long-term durability.

Key Differentiators:

- 25 PDAC-certified billing codes supporting high reimbursement and premium margins
- Proprietary manufacturing using aerospace-grade resins
- Efficient unit economics and scalable infrastructure
- Independently tested to support users up to 500 lbs
- Pediatric and adult lines with adjustable heel tensioning
- Fully turnkey operations, supply chain, and brand presence

Customer acquisition is driven by strategic B2B relationships with clinicians, supported by direct marketing. A new multi-channel campaign targeting trade media and social platforms is underway to accelerate distribution and brand visibility.

Buyer’s Advantage:

- No legal, compliance, or investigative issues
- Fully operational and regulatory-compliant platform
- National scalability with minimal capital investment
- Marketing remains the primary untapped growth lever
- High barrier to entry: $10M+ and 5+ years to match product and PDAC approvals

Starting a prosthetic foot company from scratch would require substantial capital, regulatory hurdles, and years of R&D. This opportunity offers an investor or acquirer a fully operational and scalable solution ready for rapid national or international expansion.